Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Original Article

Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial

Sun Young Yim, Sung Hwan Lee, Seung-Woo Baek, Bohwa Sohn, Yun Seong Jeong, Sang-Hee Kang, Kena Park, Hyewon Park, Sunyoung S. Lee, Ahmed O. Kaseb, Young Nyun Park, Sun-Hee Leem, Michael A. Curran, Ji Hoon Kim, Ju-Seog Lee

Clin Mol Hepatol. 2024;30(4):807-823. Published online July 23, 2024

DOI: https://doi.org/10.3350/cmh.2024.0333

View: 1961 Download: 251 Web of Science: 1 Crossref: 2

Review

The mutational landscape of hepatocellular carcinoma

Ju-Seog Lee

Clin Mol Hepatol. 2015;21(3):220-229. Published online September 30, 2015

DOI: https://doi.org/10.3350/cmh.2015.21.3.220

View: 14956 Download: 388 Web of Science: 97 Crossref: 87

Correspondence

Correspondence on Letter regarding “Comprehensive Analysis of Transcriptomic Biomarkers for Predicting Response to Atezolizumab Plus Bevacizumab Immunotherapy in Hepatocellular Carcinoma.”

Sung Hwan Lee, Sun Young Yim, Ji Hoon Kim, Sunyoung S Lee, Ahmed O Kaseb, Peng Wei, Ju-Seog Lee

Received September 23, 2024 Accepted September 28, 2024

DOI: https://doi.org/10.3350/cmh.2024.0828 [Accepted]

View: 351 Download: 21

Correspondence on Letter regarding “Transcriptomic signature in advanced hepatocellular carcinoma tissue to predict combination immunotherapy response.”

Sung Hwan Lee, Sun Young Yim, Ji Hoon Kim, Sunyoung S. Lee, Ahmed O. Kaseb, Ju-Seog Lee

Received September 23, 2024 Accepted October 2, 2024

DOI: https://doi.org/10.3350/cmh.2024.0829 [Accepted]

View: 282 Download: 15

Correspondence on Letter regarding “Personalized Approaches to the Treatment of Hepatocellular Carcinoma Using Immune Checkpoint Inhibitors”

Sun Young Yim, Sung Hwan Lee, Ji Hoon Kim, Sunyoung S Lee, Ahmed O Kaseb, Ju-Seog Lee

Received September 23, 2024 Accepted October 2, 2024

DOI: https://doi.org/10.3350/cmh.2024.0830 [Accepted]

View: 238 Download: 7

1 |

Viewed By 5101	MAFLD: How is it different from NAFLD?
Viewed By 5072	Examining the therapeutic landscape of beta-blockers in portal hypertension
Viewed By 4502	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4476	Global incidence and prevalence of nonalcoholic fatty liver disease
Viewed By 4363	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

Cited By 248	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 198	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 145	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 138	MAFLD: How is it different from NAFLD?
Cited By 113	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach

Search